Depression and Anxiety Are Not Character Flaws. They Are Measurable Biological States.

What Drives Depression and Anxiety?

The most consistent biological finding in depressed patients is neuroinflammation. Elevated IL-6, TNF-a, and CRP correlate directly with depressive severity and predict antidepressant non-response. The mechanism is the IDO pathway: systemic inflammation activates indoleamine 2,3-dioxygenase, diverting tryptophan away from serotonin toward inflammatory kynurenine metabolites. The result is simultaneously reduced serotonin, reduced BDNF (the brain's maintenance and neuroplasticity molecule), and increased neuroinflammation, all from the same upstream inflammatory driver. Addressing the inflammation producing the neurotransmitter deficiency is more mechanistically complete than addressing the deficiency alone.

BDNF insufficiency is a parallel and connected driver. BDNF supports neuronal survival, drives new synaptic connections, and enables the hippocampal neurogenesis that emotional resilience and antidepressant response both depend on. BDNF falls with cortisol elevation, chronic inflammation, poor sleep, and sedentary behavior, the same conditions producing mood disorders. Antidepressant response consistently correlates with BDNF elevation: patients whose BDNF rises show better outcomes.

The gut-brain axis adds another layer. 95% of the body's serotonin is produced in the gut under the influence of microbiome composition. Gut dysfunction impairs serotonin production and allows inflammatory metabolites to travel up the vagus nerve, directly worsening the neuroinflammatory state driving mood symptoms. HPA axis dysregulation, where chronic cortisol elevation suppresses BDNF, impairs hippocampal neurogenesis, and drives depressive symptomatology, completes the picture.

Who the Mood Protocol Is For

This protocol is built for patients who are dealing with one or more of the following:

• Depression, anxiety, or persistent low mood that has not fully responded to antidepressants or therapy alone
• Mood symptoms alongside inflammatory conditions, chronic illness, gut dysfunction, or post-viral illness
• Interest in understanding the biological drivers behind their mood and addressing them directly
• Significant fatigue, sleep disruption, or cognitive symptoms alongside mood concerns, suggesting shared upstream biology

How the Mood Protocol Works

The baseline panel for this protocol includes inflammatory markers (hs-CRP, IL-6), Vitamin D, cortisol curve, homocysteine, gut markers, B12 and folate (methylation support), and where indicated, neurotransmitter markers. The protocol moves through three stages targeting neuroinflammation, BDNF, the gut-brain axis, and HPA axis dysregulation simultaneously.

What the Protocol May Include: high-DHA omega-3 for reducing the pro-inflammatory cytokines activating IDO and driving neurotransmitter depletion (meta-analyses show consistent benefit for EPA and DHA in depression); ashwagandha for cortisol reduction (15 to 30% in published RCTs), directly protecting BDNF and hippocampal neurogenesis; Vitamin D for BDNF production through hippocampal receptors; magnesium glycinate for NMDA receptor modulation and deep sleep architecture supporting overnight BDNF production; and L-glutamine for gut barrier repair, addressing the serotonin pathway at its source. As the protocol advances, injectable vitamins at the clinic deliver NAD IV for neuronal energy and sirtuin mood-relevant gene expression, glutathione for the IDO-activating oxidative neuroinflammation, injectable magnesium for NMDA regulation, B-complex for serotonin, dopamine, and GABA synthesis cofactors, and injectable zinc for BDNF signaling and hippocampal neurogenesis. Stage 3 adds peptide therapy including Semax, the most potent available BDNF-raising intervention for patients where BDNF insufficiency is the primary driver; Selank for GABA and serotonin pathway modulation with published anxiolytic evidence and no dependence risk; PE-22-28 for direct neuroinflammation reduction and neuronal survival; BPC-157 for gut-brain axis repair and dopamine receptor modulation; and DSIP for deep sleep optimization, because overnight BDNF production and emotional processing during REM sleep are critical for mood regulation.

Stage 1 (Pathway) addresses the most foundational drivers: IDO pathway inflammation, cortisol, and gut-brain axis. Stage 2 (Roadmap) adds injectable delivery at the clinic for therapeutic neurotransmitter and neuroinflammation support. Stage 3 (Atlas) is the complete protocol for complex mood presentations, treatment-resistant depression, or patients where BDNF-targeted peptides are the next clinical step.